Advanced

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

Abrahamsson, Anna LU ; Albertsson Lindblad, Alexandra LU ; Brown, Peter Nully; Baumgartner-Wennerholm, Stefanie; Pedersen, Lars Møller; D'Amore, Francesco; Nilsson-Ehle, Herman; Jensen, Paw; Pedersen, Michael and Geisler, Christian H, et al. (2014) In Blood 124(8). p.1288-1295
Abstract
There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000-2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (HR 1.36;... (More)
There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000-2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (HR 1.36; p=0.002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3 year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3 year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n=766; HR 0.66; p=0.001) and autologous stem cell transplant (ASCT) (n=273; HR 0.55; p=0.004) were independently associated with improved overall survival in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
124
issue
8
pages
1288 - 1295
publisher
American Society of Hematology
external identifiers
  • pmid:24859361
  • wos:000342761900020
  • scopus:84907374831
ISSN
1528-0020
DOI
10.1182/blood-2014-03-559930
language
English
LU publication?
yes
id
8452843d-c019-41fd-aa2c-16b679970204 (old id 4452599)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24859361?dopt=Abstract
date added to LUP
2014-06-06 20:35:59
date last changed
2017-11-12 03:14:00
@article{8452843d-c019-41fd-aa2c-16b679970204,
  abstract     = {There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000-2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (HR 1.36; p=0.002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3 year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3 year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n=766; HR 0.66; p=0.001) and autologous stem cell transplant (ASCT) (n=273; HR 0.55; p=0.004) were independently associated with improved overall survival in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice.},
  author       = {Abrahamsson, Anna and Albertsson Lindblad, Alexandra and Brown, Peter Nully and Baumgartner-Wennerholm, Stefanie and Pedersen, Lars Møller and D'Amore, Francesco and Nilsson-Ehle, Herman and Jensen, Paw and Pedersen, Michael and Geisler, Christian H and Jerkeman, Mats},
  issn         = {1528-0020},
  language     = {eng},
  number       = {8},
  pages        = {1288--1295},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.},
  url          = {http://dx.doi.org/10.1182/blood-2014-03-559930},
  volume       = {124},
  year         = {2014},
}